P/E ratio for aTyr Pharma (ATYR)
P/E ratio as of April 2025 (TTM): -2.79
According to aTyr Pharma's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.78723. At the end of 2022 the company had a P/E ratio of -1.37.
P/E ratio history for aTyr Pharma from 2015 to 2024
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.37 | -65.55% |
| 2021 | -3.97 | 62.83% |
| 2020 | -2.44 | 330.12% |
| 2019 | -0.5673 | 32.28% |
| 2018 | -0.4289 | -76.84% |
| 2017 | -1.85 | 110.16% |
| 2016 | -0.8812 | -79.18% |
| 2015 | -4.23 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 | -72.4 | 2,496.66% | 🇺🇸 USA |
 | 36.3 | -1,400.87% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.